The lowest cost formulation should be used when clinically appropriate.  Formulations approved include:

• 1mg, 5mg tablets;
• 1mg in 1ml oral solution (Prednisolone Dompé®);
• 5mg soluble tablets - to be restricted to patients who have a genuine need e.g. swallowing difficulties. 5mg plain tablets can be dispersed in water (an off-label administration method) which may be suitable for most patients.

See separate entry for rectal formulations

• Alternative
  • Budenofalk® (3mg capsules enclosing e/c pellets)
  • Entocort® (3mg capsules enclosing e/c m/r pellets)
  • For use on consultant gastroenterologist advice only

• Oral Viscous Budesonide  unlicensed 
  • For the treatment of eosinophilic oesophagitis.
  • 0.5mg or 1mg nebule is added to 13ml of syrup and this is then mixed and swallowed. 

• Orodispersible tablet (Jorveza®) 
  • For the treatment of eosinophilic oesophagitis in adults in line with NICE 
  • Approved for the maintenance of eosinophilic oesophagitis in line with NTAG  
• 9mg MR tablet (Cortiment®) 
  • For induction of remission in patients with mild to moderate active ulcerative colitis (UC) where 5-ASA treatment is not sufficient.
  • 8 week course to be provided by secondary care.
•  4mg modified-release capsules (Kinpeygo®)  
  • Approved for treating primary IgA nephropathy in line with NICE

5mg suppositories only

See separate entry for oral prepartions

•  2mg foam enema
•  4mg suppositories (Budenofalk^®), for specialist inititiation